{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:47:42Z","timestamp":1770958062176,"version":"3.50.1"},"reference-count":29,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Angiosarcoma (AS) is a rare subtype of soft tissue sarcoma. We performed a retrospective analysis of patient characteristics, treatments and prognostic factors in patients treated in a single sarcoma center. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We reviewed records of patients treated between 1987 and 2018, categorized in 7 different subtypes according to tissue of origin and underlying risk factors. The Kaplan-Meier method was used to estimate overall survival (OS); the Cox proportional hazards model was used to study prognostic variables. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Among 134 patients, 30% had radiation-induced, 31% primary soft tissue, 24% cutaneous, 5% breast, 4% bone, 2% lymphedema-associated and 4% unknown primary AS. Key patient\/disease characteristics varied between subgroups. The median OS was 22.0 months for the entire cohort, with 28.9% with a 5-year survival. Metastasis at diagnosis was seen in 23% of patients; 38% developed metachronous metastasis. Sixty-six (49%) patients received systemic therapy; common first-line treatments were doxorubicin (48%) and paclitaxel (39%), without a significant difference in OS between agents. Younger age, breast\/radiation-induced AS, primary surgery and palliative chemotherapy were associated with better OS. Synchronous metastasis, soft tissue\/unknown primary location correlated with poor survival. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; AS is a very heterogeneous sarcoma subtype, with substantial variability in clinical presentation and survival among patient subsets. Prognosis is poor, and there is no difference in outcome comparing the 2 most frequently used chemotherapy agents in the first line, paclitaxel and doxorubicin. <\/jats:p>","DOI":"10.1159\/000516000","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T21:02:47Z","timestamp":1620162167000},"page":"322-332","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective Analysis of the Clinical Presentation, Treatment and Outcome of Angiosarcoma in a Sarcoma Referral Center"],"prefix":"10.1159","volume":"44","author":[{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herlinde","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Hompes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Christiaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raf","family":"Sciot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Jui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Meyskens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70023-1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5131-4"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26809"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/459386"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199603)61:3<170::AID-JSO2>3.0.CO;2-8"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9335-y"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm381"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31827e4e7b"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000381917"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181dbb75a"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr138"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.176"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy096"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0531-3"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2014.01.007"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11667"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/31655219"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.004"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.07.037"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3146"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8505"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26599"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200505000-00011"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/575781"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.002"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3292-7"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0749-z"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2014.3584"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/516000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/516000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:40:16Z","timestamp":1745426416000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000516000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,5,31]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1159\/000516000","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}